Photo Credit: Adrian Sulyok
Scientific Frontline: Extended "At a Glance" Summary: Multifeature Sequencing-Based Liquid Biopsy (MSLB)
The Core Concept: Multifeature sequencing-based liquid biopsy (MSLB) is an advanced diagnostic approach that analyzes multiple biological signals simultaneously from a single blood sample to detect and monitor cancer. This technique offers a comprehensive view of a tumor's characteristics without requiring invasive surgical procedures.
Key Distinction/Mechanism: Unlike traditional liquid biopsies that typically search for a single cancer-linked mutation, MSLB aggregates diverse molecular data types—including genetic, structural, and chemical alterations—to construct a broader, more complete profile of cancer biology.
Major Frameworks/Components:
- Circulating Nucleic Acids: The analysis of cell-free DNA and RNA present in the bloodstream.
- Genomic Structural Alterations: The evaluation of DNA fragment sizes and chromosomal changes.
- Epigenetic Markers: The detection of chemical modifications, specifically DNA methylation.
- Advanced Bioinformatics: The application of machine learning and complex computational methods to interpret the massive datasets generated by multi-signal analysis.
Branch of Science: Molecular Oncology, Genomics, Bioinformatics, and Clinical Pathology.
Future Application: MSLB is poised to improve the clinical monitoring of cancer patients by tracking treatment efficacy and disease progression over time, particularly when traditional tissue biopsies are unfeasible. With standardized clinical workflows, this technology may eventually enable early detection across multiple cancer types.
Why It Matters: By integrating various biological signals into one minimally invasive test, MSLB provides a dynamic and comprehensive picture of tumor development, ultimately enabling more precise and responsive personalized cancer treatments.
A single blood test could in the future provide a more comprehensive picture of cancer than current methods. In a review article published in the journal Genome Medicine, researchers at Karolinska Institutet describe how several different biological signals can be analyzed simultaneously from the same blood sample to detect and monitor cancer diseases.
Researchers and clinicians currently use so-called liquid biopsies, in which material from tumors can be detected in the blood. The method is less invasive than traditional tissue samples and can be used to monitor disease progression over time. In the current review article, researchers summarize developments in a growing field of research in which several different molecular signals are combined in the same analysis. These signals may come, among other things, from free DNA and RNA in the blood, as well as from changes in the structure of the genome and chemical markers.
The researchers call the approach "multifeature sequencing-based liquid biopsy" (MSLB). The idea is not only to look for a single change linked to cancer, but to combine several types of information to provide a broader picture of the tumor's characteristics.
"By analyzing several biological signals simultaneously from the same blood sample, we can potentially gain a more complete picture of the biology of cancer than by studying each signal separately," says Mariano A. Molina Beitia, a researcher at the Department of Laboratory Medicine, Karolinska Institutet.
The article describes several research studies in which combinations of different signals have been used to detect cancer or monitor the disease over time. For example, analyses of DNA methylation, fragment size, and chromosomal changes in blood have shown promising results for the early detection of several types of cancer. The researchers also describe how advanced bioinformatics methods and machine learning are used to interpret the large amounts of data generated.
Challenges Remain
At the same time, the researchers emphasize that the technology still faces several challenges. Many studies have been carried out in limited patient groups, and the results need to be confirmed in larger prospective studies. In addition, the methods are technically complex, and there are still no common standards for how the analyses should be performed and quality-assured across different healthcare centers.
"For the technology to be widely used in healthcare, standardized workflows, independent validation, and studies demonstrating the benefits of the analyses for patients are needed," says Daniel Hagey, a senior researcher on the study at the Department of Laboratory Medicine.
The researchers believe that the first clinical applications will most likely be in monitoring cancer patients, assessing treatment effects, and situations where repeated tissue samples are difficult to obtain. In the longer term, the method could contribute to a more integrated and dynamic picture of cancer development based on a simple blood sample.
Funding: The work was funded in part by the Center for Innovative Medicine in Region Stockholm, the Swedish Childhood Cancer Fund, the Åke Wiberg Foundation, the Swedish Cancer Society, the Felix Mindus Fund for Leukemia Research, and the Ruth and Richard Julin Foundation.
Disclaimer: The authors report no conflicts of interest.
Published in journal: Genome Medicine
Title: Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring
Authors: Mariano A. Molina, Martina De Simoni, Norbert Moldovan, Florent Mouliere, and Daniel W. Hagey
Source/Credit: Karolinska Institutet
Edited by: Scientific Frontline
Reference Number: ongy081126_01